

**“PRINCIPLES OF CLINICAL PHARMACOLOGY” COURSE****2009-2010 SCHEDULE**

**All sessions will meet Thursday evenings from 6:30 p.m. to approximately 7:45 p.m.  
in the NIH Clinical Center, Building 10, in the Lipsett Amphitheater in Bethesda, Maryland.  
Course Web Site: <http://www.cc.nih.gov/training/training/principles.html>**

September 3rd Introduction to course J. Lertora (NIH CC)

**MODULE 1: PHARMACOKINETICS:**

September 10th Clinical pharmacokinetics J. Lertora (NIH CC)  
 September 17th Chemical assay of drugs and drug metabolites S. Markey (NIH NIMH)  
 September 24th Compartmental analysis of drug distribution J. Lertora (NIH CC)  
 October 1st Drug absorption and bioavailability J. Lertora (NIH CC)  
 October 8th Use of positron emission tomography (PET) in pharmacokinetics R. Innis (NIH NIMH)  
 October 15th Effects of renal disease on pharmacokinetics J. Lertora (NIH CC)  
 October 22nd SPECIAL LECTURE: Pharmacokinetics in patients requiring renal replacement therapy A. Atkinson (Northwestern Un.) and G. Susla (MedImmune, Inc.)  
 October 29th Noncompartmental vs. compartmental approaches to PK analysis P. Vicini (Pfizer, Inc.)  
 November 5th Effects of liver disease on pharmacokinetics J. Lertora (NIH CC)  
 November 12th Population pharmacokinetics R. Miller (Pfizer, Inc.)

**MODULE 2: DRUG METABOLISM AND TRANSPORT:**

November 19th Pathways of drug metabolism S. Markey (NIH NIMH)  
 December 3rd Drug Interactions S. Penzak (NIH CC)  
 December 10th Pharmacogenomics D. Flockhart (IUPUI)  
 December 17th Biochemical mechanisms of drug toxicity L. Pohl (NIH NHLBI)  
 January 7th SPECIAL LECTURE: P-glycoprotein and drug transport M. Gottesman (NIH OIR) and R. Innis (NIH NIMH)  
 January 14th Equilibrative and concentrative drug transport J. Ware (Genentech, Inc.)

**MODULE 3: ASSESSMENT OF DRUG EFFECTS:**

January 21st Dose response and concentration response analysis J. Lertora (NIH CC)  
 January 28th Disease progression models and clinical trial simulation D. Mould (Projections Research, Inc.)  
 February 4th Physiological and laboratory markers of drug effect J. Woodcock (FDA)

**MODULE 4: OPTIMIZING AND EVALUATING PATIENT THERAPY:**

February 11th Drug therapy in pregnant and nursing women M. Fredericksen (Northwestern Un.)  
 February 18th Developmental and pediatric pharmacology J. van den Anker (Children's National Medical Center)  
 February 25th Drug therapy in the elderly D. Abernethy (U.S. Pharmacopeia)  
 March 4th Quality assessment of drug therapy C. Daniels (UCSD)  
 March 11th Clinical analysis of adverse drug reactions C. Chamberlain (NIH CC)

**MODULE 5: DRUG DISCOVERY AND DEVELOPMENT:**

March 18th Drug discovery E. Sausville (Un. of Maryland Medical System)  
 March 25th Pre-clinical drug development C. Takimoto (Centocor R&D, Inc./Johnson & Johnson)  
 April 1st Animal scale up and Phase I studies R. Dedrick (NIH NIBIB) and J. Collins (NCI NIH)  
 April 8th Role of the FDA in guiding drug development C. Peck (CDDS, UCSF)  
 April 15th Design of clinical drug development programs C. Breder (FDA)  
 April 22nd Development of biotechnology products and large molecules P. Garzone (PD3G Consulting)